Physician profile
Michael L Bell
NPI 1144292590
$2,060.64
in general payments reported to CMS, 2019-2025
28 companies · $86.06 in 2025
The $86.06 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $607 · 2020: $115 · 2021: $235 · 2022: $180 · 2023: $496 · 2024: $343 · 2025: $86.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $924.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $924.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $487.66 | 2019-2024 | Vumerity, Tysabri |
| Ucb, INC. | $229.66 | 2019-2024 | Fintepla, Zilbrysq |
| Abbvie INC. | $202.69 | 2021-2024 | Ubrelvy |
| Argenx US, INC. | $173.12 | 2023-2024 | Vyvgart, Vyvgart Hytrulo |
| Boston Scientific Corporation | $116.92 | 2019-2025 | Watchman Access System |
| Genzyme Corporation | $89.87 | 2019-2022 | |
| Tg Therapeutics, INC. | $87.45 | 2024 | |
| Abbott Laboratories | $82.55 | 2023 | Amplatzer Talisman |
| Novartis Pharmaceuticals Corporation | $72.42 | 2019-2023 | |
| Alexion Pharmaceuticals, INC. | $57.18 | 2019 | |
| Sunovion Pharmaceuticals INC. | $50.94 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $48.80 | 2023 | Lynparza |
| Acorda Therapeutics, INC | $44.60 | 2019 | |
| Lilly USA, LLC | $35.42 | 2020-2024 | Kisunla |
| Medtronic USA, INC. | $32.42 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $30.58 | 2019 | |
| Nevro Corp. | $26.31 | 2022 | |
| Sumitomo Pharma America, INC. | $25.54 | 2023 | Aptiom |
| Eisai INC. | $23.99 | 2024 | |
| Vertical Pharmaceuticals, LLC | $22.46 | 2019 | |
| Jazz Pharmaceuticals INC. | $18.00 | 2019 | |
| Emd Serono, INC. | $17.92 | 2019 | |
| Acadia Pharmaceuticals INC | $16.67 | 2023 | Daybue |
| Neurelis, INC. | $16.46 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $13.53 | 2023 | Austedo Xr |
| Corium, LLC | $13.25 | 2023 | Adlarity |
| Biohaven Pharmaceutical Holding Company LTD. | $12.97 | 2022 | |
| Csl Behring | $11.26 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.